Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1035-1040

  Li, Zhengguang ^a   Li, Xingyi ^b   Cao, Zhixing ^b   Xu, Youzhi ^b   Lin, Hongjun ^b   Zhao, Yinglan ^b   Wei, Yuquan ^b   Qian, Zhiyong ^b  

^a SOOCHOW UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Antitumor; Camptothecin; Myeloma; N,N,N trimethyl chitosan

Indexed keywords

CAMPTOTHECIN; CHITOSAN; N,N,N TRIMETHYL CHITOSAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COLLOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NANOPARTICLES; SOLUBILITY; TIME FACTORS; TOPOISOMERASE I INHIBITORS; TUMOR BURDEN;

EID: 84863039498     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1635     Document Type: Article

References (50)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Rajkumar SV and Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80: 1371-1382, 2005. (Pubitemid 41395971)
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
4. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
5. Munshi NC: Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program 2008: 297, 2008.
6. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
7. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985. (Pubitemid 16211028)
8. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
9. Takimoto CH, Wright J and Arbuck SG: Clinical applications of the camptothecins. Biochim Biophys Acta 1400: 107-119, 1998. (Pubitemid 28475098)
10. Topcu Z: DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26: 405-416, 2001.
11. Bredholt T, Dimba EA, Hagland HR, et al: Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol Cancer 8: 101, 2009.
12. Garcia-Carbonero R and Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641-661, 2002. (Pubitemid 34742090)
13. Hatefi A and Amsden B: Camptothecin delivery methods. Pharm Res 19: 1389-1399, 2002. (Pubitemid 35266542)
14. Kehrer DF, Soepenberg O, Loos WJ, Verweij J and Sparreboom A: Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 12: 89-105, 2001. (Pubitemid 32207358)
15. Bodley AL, Wani MC, Wall ME and Shapiro TA: Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 50: 937-942, 1995.
16. Haluska P, Rubin E and Verschraegen CF: Topoisomerase-I inhibitors in gynecologic tumors. Hematol Oncol Clin North Am 13: 43-61, vii-viii, 1999.
17. Kawano K, Watanabe M, Yamamoto T, et al: Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 112: 329-332, 2006.
18. Sun FX, Tohgo A, Bouvet M, et al: Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res 63: 80-85, 2003. (Pubitemid 36070423)
19. Zu YG, Li QY, Fu YJ and Wang W: Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg Med Chem Lett 14: 4023-4026, 2004.
20. van Hattum AH, Pinedo HM, Schluper HM, Erkelens CA, Tohgo A and Boven E: The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol 64: 1267-1277, 2002. (Pubitemid 35257921)
21. Akimoto K, Kawai A and Ohya K: Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous aolution. Chem Pharm Bulletin 42: 2135-2138, 1994. (Pubitemid 24341590)
22. Hanson BA, Schowen RL and Stella VJ: A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm Res 20: 1031-1038, 2003. (Pubitemid 36774274)
23. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842, 1994. (Pubitemid 24164661)
24. Burke TG, Staubus AE, Mishra AK and Malak H: Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114: 8318-8319, 1992.
25. Cortesi R, Esposito E, Maietti A, Menegatti E and Nastruzzi C: Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int J Pharm 159: 95-103, 1997. (Pubitemid 28062814)
26. Watanabe M, Kawano K, Yokoyama M, Opanasopit P, Okano T and Maitani Y: Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 308: 183-189, 2006. (Pubitemid 43097251)
27. Shenderova A, Burke TG and Schwendeman SP: The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 16: 241-248, 1999.
28. Tong W, Wang L and D'Souza MJ: Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm 29: 745-756, 2003. (Pubitemid 36899881)
29. Chandy T and Sharma CP: Chitosan-as a biomaterial. Biomater Artif Cells Artif Organs 18: 1-24, 1990.
30. Kotzé AF, Lueßen HL, de Boer AG, Verhoef JC and Junginger HE: Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci 7: 145-151, 1998. (Pubitemid 29056237)
31. Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC and Junginger HE: N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 14: 1197-1202, 1997. (Pubitemid 27432543)
32. Jintapattanakit A, Mao S, Kissel T and Junyaprasert VB: Physicochemical properties and biocompatibility of N-trimethyl chitosan: effect of quaternization and dimethylation. Eur J Pharm Biopharm 70: 563-571, 2008.
33. Peng X and Zhang L: Surface fabrication of hollow microspheres from N-methylated chitosan cross-linked with gultaraldehyde. Langmuir 21: 1091-1095, 2005. (Pubitemid 40184813)
34. Peng X, Zhang L and Kennedy JF: Release behavior of microspheres from cross-linked N-methylated chitosan encapsulated ofloxacin. Carbohydr Polym 65: 288-295, 2006. (Pubitemid 44142093)
35. Zhilei L, Steenekamp JH and Hamman JH: Cross-linked cationic polymer microparticles: effect of N-trimethyl chitosan chloride on the release and permeation of ibuprofen. Drug Dev Ind Pharm 31: 311-317, 2005. (Pubitemid 40463974)
36. Li X, Kong X, Zhang J, et al: A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids. J Pharm Sci 100: 232-241, 2011.
37. Yuan ZP, Chen LJ, Fan LY, et al: Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res 12: 3193-3199, 2006.
38. Muther RS and Bennett WM: Effects of dimethyl sulfoxide on renal function in man. JAMA 244: 2081-2083, 1980. (Pubitemid 10024430)
39. Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53: 3186-3192, 1993. (Pubitemid 23210333)
40. Rajkumar SV: Multiple myeloma. Curr Probl Cancer 33: 7-64, 2009.
41. Sirohi B and Powles R: Multiple myeloma. Lancet 363: 875-887, 2004. (Pubitemid 38368839)
42. Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937, 2002. (Pubitemid 37328894)
43. Donato ML, Aleman A, Champlin RE, et al: High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45: 755-759, 2004. (Pubitemid 38256038)
44. Kraut EH, Crowley JJ, Wade JL, et al: Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 16: 589-592, 1998. (Pubitemid 28135604)
45. Kraut EH, Young D, Farag S, James AG and Solove RJ: Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leuk Res 29: 1233-1234, 2005. (Pubitemid 41169243)
46. Watanabe M, Kawano K, Toma K, Hattori Y and Maitani Y: In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release 127: 231-238, 2008.
47. Rinaudo M: Chitin and chitosan: properties and applications. Prog Polym Sci 31: 603-632, 2006.
48. Cardile V, Frasca G, Rizza L, et al: Improved adhesion to mucosal cells of water-soluble chitosan tetraalkylammonium salts. Int J Pharm 362: 88-92, 2008.
49. Snyman D, Hamman JH and Kotze AF: Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev Ind Pharm 29: 61-69, 2003. (Pubitemid 36205882)
50. Mourya VK and Inamdar NN: Trimethyl chitosan and its applications in drug delivery. J Mater Sci Mater Med 20: 1057-1079, 2009.